| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and lowers the price...
Barclays analyst Gena Wang maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and raises the price target fr...
Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and lowers the price target from $455...
Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2025 sales outlook from $11.850 billion-$12.000 billion to $11.900 billion-$12.00...
Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.80 per share which beat the analyst consensus estimate o...
Wall Street opened the week on a mixed note on Monday.